Pfizer’s Lyrica Is “Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Neurontin follow-on drug pregabalin receives second “approvable” decision in two months. Pfizer is looking to convert Neurontin patients to the successor product in the face of gabapentin generics.
You may also be interested in...
Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety
The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.
Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety
The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.
Ivax Launches Neurontin Generic As User Fee Date For Pfizer's Pregabalin Nears
Non-AB-rated gabapentin tablets launch "at risk" less than two weeks before the estimated Aug. 30 user fee deadline for Pfizer's follow-on drug Lyrica. Pfizer is seeking a temporary restraining order against Ivax.